Treatment of the symptoms of schizophrenia: A combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents

International Clinical Psychopharmacology

Volumn 16, Issue 5, 2001, Pages 265-274

  Glick, I D ^a   Lemmens, P ^b   Vester Blokland, Estelle ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c NV ORGANON   (Netherlands)

Author keywords

Double blind studies; Efficacy; Haloperidol; PANSS; Risperidone; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERPHENAZINE; PLACEBO; REMOXIPRIDE; RISPERIDONE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGED; ALEXITHYMIA; ANXIETY; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SYMPTOM;

EID: 0034836902     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200109000-00003     Document Type: Article

References (46)

1. The role of serotonin in the pathophysiology and treatment of schizophrenia
2. Practice guideline for the treatment of patients with schizophrenia
3. Negative v positive schizophrenia. Definition and validation
4. Anticholinergics and amantadine
5. Long-term treatment of mood disorders in schizophrenia
6. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients
7. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
8. Serotonin, schizophrenia and antipsychotic drug action
9. Domain of psychopathology: An approach to the reduction of heterogeneity in schizophrenia
10. Radioreceptor binding profile of the atypical antipsychotic olanzapine
11. Risperidone in the treatment of negative symptoms of schizophrenia: A meta-analysis
12. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
13. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study
14. Molecular pathology of schizophrenia: More than one disease process?
15. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs
16. The catatonic syndrome
17. Depression and social adjustment among chronic schizophrenia outpatients
18. Cognitive functioning in schizophrenia
19. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
20. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations
21. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: A double-blind parallel-group trial
22. The complex problem of treatment
23. Management strategies for the treatment of schizophrenia
24. Maintenance pharmacotherapy in schizophrenia
25. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
26. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: Preliminary findings
27. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes
28. A combined analysis of double-blind studies with risperidone versus placebo and other antipsychotic agents: Factors associated with extrapyramidal symptoms
29. Dimensions positives et négatives dans les schizophrénies
30. Five factor model of schizophrenia: Replication across samples
31. Principal component analysis of the Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia
32. Risperidone in the treatment of schizophrenia
33. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials
34. Threats to the validity of research syntheses
35. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: A parallel group double-blind comparative trial
36. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study
37. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome
38. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia
39. Depressive symptoms in acute schizophrenic inpatients
40. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol
41. Effects of risperidone on affective symptoms in patients with schizophrenia
42. Comparison of patients with early, typical-, and late-onset affective psychosis
43. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
44. The effect of risperidone on cognition in patients with schizophrenia
45. A biological and pharmacological suggestion about certain mental disorders